Parasym

Parasym is a neurotechnology company dedicated to developing innovative neuromodulation products that harness the therapeutic mechanisms of the vagus nerve to restore health. The company's flagship product is a non-invasive device that delivers targeted electrical micropulses to the vagus nerve through an ear clip electrode. This stimulation aims to favorably alter the nervous system and reduce inflammation in various conditions.

Parasym's neuromodulation device has been clinically proven to improve cardiac mechanics, quality of life, and reduce inflammatory markers in patients with heart failure with preserved ejection fraction (HFpEF). In a randomized controlled trial conducted in 2022, patients using the device for an hour daily over three months experienced significant improvements in global longitudinal strain, a core indicator of cardiac mechanics, and reductions in pro-inflammatory cytokines like Interleukin-8 and Tumor Necrosis Factor-alpha.

The company has also explored the potential of its device in treating long COVID, a condition characterized by persistent symptoms after recovering from Covid-19 infection. Clinical trials revealed that around 40% of patients with chronic fatigue, brain fog, and widespread pain post-COVID experienced positive responses to Parasym's neuromodulation therapy.

Parasym's device has been designated a Non-Significant Risk (NSR) by the FDA and is currently CE-marked, allowing its use in clinical practice and research settings. As of 2024, the company has over 60 clinical partnerships across four continents and has completed over 1,000,000 treatment sessions.